GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning

There is a labeled interaction between a GLP-1 medicine and the contraceptive pill, and it belongs to tirzepatide. Mounjaro and Zepbound both tell prescribers to steer a patient off a swallowed hormonal method, or to layer a barrier method on top of it, for four weeks from the first injection and again for four weeks after every increase in dose. The three semaglutide labels — Ozempic, Wegovy and the oral tablets — carry no such advisory at all. We read all five on August 15, 2026 to check that, because the difference is the whole point.

What the tirzepatide labels tell prescribers

Section 8.3 of the Mounjaro label is where it lives. It says the drug can lower how well a swallowed hormonal contraceptive works, because the stomach is handing its contents on more slowly, and that the slowing is at its most pronounced after the very first dose before easing off. The instruction that follows is to move the patient off the swallowed method or add a barrier one, and to keep that in place for four weeks from the start of treatment and for four weeks following every step up in dose.^[1] Zepbound carries the identical instruction with its clauses arranged differently, over the same two four-week spans.^[2]

Both labels repeat it in three separate places — the Highlights box at the top, the drug interactions section, and the counseling text a prescriber is meant to deliver — which is a fair signal of how much weight Eli Lilly puts on it. The version written for patients rather than clinicians is the plainest of the lot.

Birth control pills by mouth may not work as well while using MOUNJARO.

— Mounjaro medication guide, SPL version 38, effective April 22, 2026

One sentence elsewhere in the same section does more work than any of that. The labels state that hormonal contraception delivered by any route other than the mouth should not be affected.^[1][2] That is the manufacturer drawing the boundary itself, and it is what decides whether any of this applies to you.

What the semaglutide labels do instead

None of the three carry a contraception advisory. Ozempic's label mentions an oral contraceptive exactly once, in a figure legend inside the clinical pharmacology section showing that ethinylestradiol and levonorgestrel exposure was measured and was not meaningfully changed.^[3] Wegovy and the oral semaglutide label do not use the word at all; both list ethinyl estradiol and levonorgestrel among the drugs whose pharmacokinetics showed no clinically significant difference alongside semaglutide.^[4][5]

So the honest statement is that semaglutide also slows the stomach, and its labels also warn about oral medications generally, but the specific contraceptive advisory was not written for it. A pharmacology review of every approved GLP-1 agonist reached the same split independently: interactions driven by delayed gastric emptying are mostly clinically insignificant across the class, with tirzepatide and oral contraceptives named as one of the two exceptions worth monitoring.^[6]

The measurement underneath it

Both tirzepatide labels publish the study the advisory came from. A combined oral contraceptive was given with a single 5 mg dose of tirzepatide, and peak concentrations of ethinyl estradiol, norgestimate and norelgestromin fell by 59%, 66% and 55%. Total exposure across the day fell far less — by 20%, 21% and 23% — and the time to peak concentration was pushed back by two and a half to four and a half hours.^[1][2]

Read that pattern and the advisory makes sense. The hormone still arrives; it arrives later and in a flatter curve, because the stomach handed it over more slowly. The same labels show the same effect on acetaminophen, and show it fading: after four to six weeks of continued dosing there was no meaningful impact on acetaminophen peak concentration at all.^[1][2] That is why the window is four weeks rather than permanent, and why it re-opens at each step up. The slowed stomach behind it is the same mechanism that produces most of the drug's better-known effects, which we set out in what the tirzepatide record does and does not cover.

Which methods this touches

The label's phrase is oral hormonal contraceptives. Everything hinges on the route, not on the hormone. A 2026 review in a contraception journal reaches the practical version of the same conclusion: while someone is on one of these drugs, and particularly while gastrointestinal side effects are active, non-oral hormonal methods and long-acting reversible contraception are the more dependable choices.^[8]

• Affected, per the label: anything swallowed. Combined pills and progestin-only pills both go through the stomach, and the stomach is the whole mechanism.
• Not affected, per the label: hormonal methods that skip the gut. The patch, the vaginal ring, the injection and the implant deliver through skin, mucosa or muscle, and a hormonal intrauterine device releases into the uterus. A copper IUD involves no hormone at all.
• Barrier methods are unaffected by definition, which is why the label offers adding one as the alternative to switching.
• We could not find emergency contraception addressed in any of the five labels. Oral emergency contraception is swallowed, so the same mechanism would apply in principle, but no label we read says so and we are not going to fill that gap ourselves. It is a question for a pharmacist or prescriber.

Counting the four weeks

The window is not a single month at the start of treatment. It runs four weeks from the first dose, and then four weeks again from each increase, and GLP-1 treatment is built around a ladder of increases spread over the first several months. On a stepped schedule the covered period recurs more often than most people expect from reading the advisory once.

We are not going to lay out a dose schedule here, and you should not calculate your own window from a general article. Your prescriber knows which step you are on and when the next one is planned. Ask them to mark the dates. Our companion piece on how long GLP-1 side effects last explains why the escalation phase, rather than the calendar month, is the coordinate that matters for most of these drugs' behavior.

The conversation that mostly is not happening

A 2026 study of 382 women aged 18 to 44 with type 2 diabetes, recruited across 38 Chicago health centers, found that half had been prescribed a GLP-1 receptor agonist. Among the 194 who had, 54.6% intended a future pregnancy and 40.7% were using hormonal contraception or an intrauterine device. Fewer than one in eight reported that pregnancy intention, contraception or preconception health had come up at their most recent visit.^[7]

Women with limited health literacy were less likely still to have had the preconception conversation: 6.3% against 18.4%.^[7] That is a gap in the appointment, not in the label. If nobody has raised it with you, that is common, and it is a reason to raise it yourself rather than a sign it does not apply.

What to raise with a prescriber

1. Which molecule am I actually on? The advisory is tirzepatide's. If a telehealth service sold you "a GLP-1" without naming it, that is the first thing to establish.
2. Am I inside a four-week window right now — from starting, or from the last increase — and when does the next increase fall?
3. Is switching method or adding a barrier the better fit for me? The label offers both and does not rank them. Your prescriber can.
4. Does this change if I have been vomiting or badly nauseated? A pill that does not stay down is a separate problem from a pill absorbed slowly, and it applies whichever molecule you are on.
5. What is the plan if I want to try for a pregnancy? That question has a different answer for each drug, and it is covered separately.

If the service that prescribed your medication is hard to reach for a question like this, that itself is worth weighing. We record who dispenses for each seller and whether a named, state-licensed pharmacy is identifiable, on our pharmacy register.